Ovid Therapeutics Inc.
OVID
$1.22
$0.087.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4,724.62% | 71.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4,724.62% | 71.05% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 4,724.62% | 71.05% | |||
| SG&A Expenses | -18.95% | -11.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.53% | 15.29% | |||
| Operating Income | 59.58% | -14.91% | |||
| Income Before Tax | 54.24% | -10.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.24% | -10.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.24% | -10.61% | |||
| EBIT | 59.58% | -14.91% | |||
| EBITDA | 59.92% | -15.30% | |||
| EPS Basic | 54.31% | -14.29% | |||
| Normalized Basic EPS | 61.10% | -29.30% | |||
| EPS Diluted | 54.31% | -12.11% | |||
| Normalized Diluted EPS | 61.10% | -29.30% | |||
| Average Basic Shares Outstanding | 0.09% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||